Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.…
Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance
Moleculin Biotech (NASDAQ: MBRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 17 employees.
The shares were at 7.740 USD on 20 November 2026, down 96.8% over 52 weeks. Its 52-week range is 3.228 USD to 253.00 USD: the price is 96.9% below the high and 139.8% above the low.
Its market capitalisation is 8.22M USD.
Moleculin Biotech reports return on equity of -223.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 7.18M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.